PCA
AZN icon

Providence Capital Advisors’s AstraZeneca AZN Stock Holding History

Providence Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-461
Closed -$55K – 340
2021
Q3 		$55K Buy
+461
New +$53.7K 0.02% 148

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Providence Capital Advisors's AZN Position: Q4 2021 in Review

Providence Capital Advisors sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 461 shares — an estimated $55K sold.

Providence Capital Advisors first reported a position in AZN in Q3 2021 and held it in 1 quarter. The position peaked at $55K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

  • Providence Capital Advisors reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
  • Providence Capital Advisors sold 461 AstraZeneca shares in Q4 2021, an estimated $55K.
  • Providence Capital Advisors first reported a position in AstraZeneca in Q3 2021 and held it in 1 quarter.
  • Providence Capital Advisors's AstraZeneca position peaked at $55K in Q3 2021.
  • 949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Providence Capital Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.